Full-Time

Director – Strategic Forecasting

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Cambridge, MA, USA

70% in-office structure required for collaboration.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Moderna referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • 10+ years of experience in forecasting, analytics or strategic planning within the biopharmaceutical or life sciences industry, with exposure to various stages of drug development highly preferred.
  • Bachelor’s degree in business, life sciences, or a related field
  • Strong understanding of revenue forecasting, including applications across pipeline programs, inline products, and enterprise planning.
  • Prior experience in oncology forecasting/ new product planning
  • Experience in gathering various types of insights (secondary research, primary research, data analytics etc.) and integrating them to inform forecasting assumptions and strategic questions.
Responsibilities
  • Develop revenue forecasts for pipeline programs in oncology as well as other therapeutic areas (e.g., infectious diseases, rare), to inform decision-making from preclinical research through commercialization.
  • Deliver scenario analyses and contextualize uncertainty to support key strategic decisions and leadership planning.
  • Gain deep insights around products and markets of interest through secondary and primary research and data analytics (partnering with insights functions as needed).
  • Act as a trusted thought partner across Research, Development and Commercial stakeholders to contribute forecasting insights in cross-functional forums.
  • Lead the integration of program-level forecasts into broader portfolio models, ensuring alignment with Moderna’s operational and enterprise planning objectives.
  • Stay ahead of industry trends, competitive developments, and market dynamics to provide forward-looking insights and shape Moderna’s strategic planning processes.
Desired Qualifications
  • Advanced degree (MBA, MS, PhD) preferred.
  • Strategic thinking skills with the ability to synthesize complex data and insights into clear, actionable recommendations.
  • Proven ability to partner cross-functionally and influence stakeholders across R&D, Commercial, and Finance.
  • Expertise in building and interpreting strategic forecasts, portfolio models, and scenario planning analyses.
  • Specific experience in oncology forecasting and analytics (e.g., patient flow modeling, claims analysis etc.).
  • Knowledge of therapeutic area landscapes, market dynamics, and competitive intelligence frameworks.
  • Strong communication and presentation skills to effectively convey insights and recommendations to executive leadership.
  • Experience supporting LRP, S&OP, or other enterprise-level financial and operational planning processes.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells communicate and produce proteins necessary for biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it leverages the body's own mechanisms to generate therapeutic proteins rather than relying on pre-made drugs. Moderna's goal is to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's collaboration with Merck aims to launch a cancer vaccine by 2027.
  • The approval of mRESVIA in Australia and the UK boosts Moderna's market presence.
  • A new biomanufacturing training program could enhance Moderna's production capabilities.

What critics are saying

  • Moderna faces a lawsuit with Pfizer and BioNTech over mRNA vaccine patents.
  • Allegations of bribing children for trials could damage Moderna's reputation.
  • HHS review of the bird flu vaccine contract may delay Moderna's strategic plans.

What makes Moderna unique

  • Moderna is pioneering mRNA technology as a new class of medicines.
  • The company has expanded its pipeline beyond COVID-19 to include cancer and RSV.
  • Moderna's mRNA vaccines have received regulatory approvals in multiple countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

5%
Labiotech
May 2nd, 2025
From Pandemic Spotlight To Post-Covid Crossroads: What Happened To These Biotech Players?

Newsletter Signup - Under Article / In Page"*" indicates required fields In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop vaccines and therapeutics that could curb a once-in-a-century global emergency. While pharma giants like AstraZeneca and Johnson Johnson also played prominent roles, much of the momentum and risk was carried by smaller biotech players suddenly thrown onto the global stage. For a brief moment, it seemed like these companies might reshape the pharmaceutical landscape for good.Fast forward to 2025, and the picture is far more complex.Some, like Moderna and BioNTech, used the momentum to build expansive pipelines beyond COVID-19, branching into cancer, flu, RSV, and other diseases. Others, however, are now scaling down, pivoting, or fading from view entirely. Just this month, companies including GeoVax, CastleVax, and Vaxart revealed they were told to halt their government-backed work on next-generation COVID vaccines under the Biden-era Project NextGen, casting doubt on the long-term strategic value of these initiatives

Pulmonology Advisor
Apr 30th, 2025
HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine

Moderna is testing a pandemic-focused vaccine for avian influenza A(H5N1).

Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.

Notas de Prensa
Apr 7th, 2025
Moderna to showcase its extensive research on Infectious Diseases at ESCMID 2025.

Moderna, Inc. (NASDAQ:MRNA) announces that it will present at the World Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), which will be held in Vienna, Austria, from April 11 to 15, 2025, its research in multiple areas of infectious diseases, such as COVID-19, influenza, respiratory syncytial virus, cytomegalovirus, norovirus, and mpox.

PharmiWeb
Mar 31st, 2025
Moderna Receives Australian Therapeutic Goods Administration Approval For Rsv Vaccine For Older Adults

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19."We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna. "This approval underscores our commitment to protecting older adults from RSV-related respiratory diseases. We look forward to supplying mRESVIA from our Melbourne facility to older Australians vulnerable to RSV in the future."RSV is a highly contagious respiratory virus that causes a substantial burden of disease, particularly in older adults. In the 2024 Australian winter period, RSV laboratory-notified cases in adults aged 65 and older were nearly two-thirds the number of influenza cases in the same age group.2 90% of RSV-related deaths reported nationally occurred in those aged 60 years and older, underscoring its potential for severe impact on older Australians.2The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.About mRESVIA (Respiratory Syncytial Virus Vaccine)mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells